Doxy PEP Does Not Lower Risk of STIs in Cisgender Women : vi

Postexposure prophylaxis with doxycycline has been shown to significantly reduce the risk of STIs in men and transgender women. Now a study looks at its efficacy in cisgender women taking HIV PrEP.

Related Keywords

Kenya , Alabama , United States , Jenell Stewart , Reneea Heffron , Centers For Disease , University Of Alabama Birmingham , Heersink School Of Medicine , University Of Minnesota , Department Of Medicine , Opportunistic Infections , Women Bear , Disease Control , East Africa , Heersink School , Alabama Birmingham , Medscape Medical , Antiretroviral Therapy , Antiretroviral Therapy Art , Art , Atazanavir , Darunavir , Travirine , Ipranavir , Herapy Antiretroviral , Hiv Infection , Shiv , Pre Exposure Hiv Prophylaxis , Hiv Prep , Reexposure Hiv Prophylaxis , Social Determinants Of Health , Pregnancy , Prophylaxis , Transgender , Adherence , Dherence To Medication Issues For Patients , Chlamydial Infection , Chlamydia , Tissue , Gonorrhea , Syphilis , Stanato ,